Boletín Clínico, Vol. 03, No. 06. Marzo

Biblioteca de la Facultad de Medicina de la Universidad de Antioquia y de la Academia de Medicina de Medellín * Sanidad de Medellín. Resolución No. 5 * Bubón climático algunas anotaciones clínicas y terapéuticas. Pag.335-358 * El tratamiento de la sífilis. Pag.359-371 * Fiebre perniciosa. (Observaciones clínicas). Pag.372-375 * Evolución del ornithodorus talaje. Pag.376-377 * Tesis de la Facultad. Enfermedad de Nicolas Favre y reacción de Frei. Pag.378-379 * Urografía intravenosa. Pag.379 * Urografía intravenosa. Pag.379 * Donativos a la Biblioteca de la Faculta de Medicina. Pag.380 * Sanidad de Medellín. Pag.381-389Sanidad de Medellin. Sanidad de Medellin anexo Bubon climatico; algunas anotaciones clinicas y terapeuticas Uribe Escobar, Gustavo p.335-358 El tratamiento de la sifilis Correa, Daniel p. 359-371 Fiebre perniciosa (observaciones clinicas) Arango Trujillo, Joaquin p.372-375 Evolucion del Ornithodorus Talaje Botero Jaramillo, Luis Eduardo p.376-377 Enfermedad de Nicolas Favre y reaccion de Frei Martinez Echeverri, Miguel p.378-379 Urografia intravenosa Echeverri Duque, Martiniano p.379 Sanidad de Medellin Sanidad de Medellin p.381-38

Anales de la Academia de medicina de Medellín, Año 1, No. 08. Septiembre. 1888. Primera época

Fiebre larvada y diabetes azucarada intermitente. Pag.207-210 * Escleroderma o trofoneurosis diseminada. Pag.210-215 * Trofoneurosis. Pag.215-216 * Envenamiento por la analgesina. Pag.217 * Manzanillo y Manzanilla. Pag.217-222 * Informe de una comisión. Pag.222-224 * El Tuntun. Pag.224-227 * Algunos Hipnoticos. Pag.227- 228 * Incompatabilidad química de algunas sustancias medicinales. Pag.228-232 * Patología de gusano de seda. Pag.232-23

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.

Background: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB levels and apoB lowering hold incremental predictive information on residual risk after acute coronary syndrome beyond that provided by low-density lipoprotein cholesterol is uncertain. Methods: The ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) compared the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome and elevated atherogenic lipoproteins despite optimized statin therapy. Primary outcome was major adverse cardiovascular events (MACE; coronary heart disease death, nonfatal myocardial infarction, fatal/nonfatal ischemic stroke, hospitalization for unstable angina). Associations between baseline apoB or apoB at 4 months and MACE were assessed in adjusted Cox proportional hazards and propensity score–matched models. Results: Median follow-up was 2.8 years. In proportional hazards analysis in the placebo group, MACE incidence increased across increasing baseline apoB strata (3.2 [95% CI, 2.9–3.6], 4.0 [95% CI, 3.6–4.5], and 5.5 [95% CI, 5.0–6.1] events per 100 patient-years in strata 35–<50, and ≤35 mg/dL, respectively). Compared with propensity score–matched patients from the placebo group, treatment hazard ratios for alirocumab also decreased monotonically across achieved apoB strata. Achieved apoB was predictive of MACE after adjustment for achieved low-density lipoprotein cholesterol or non–high-density lipoprotein cholesterol but not vice versa. Conclusions: In patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, MACE increased across baseline apoB strata. Alirocumab reduced MACE across all strata of baseline apoB, with larger absolute reductions in patients with higher baseline levels. Lower achieved apoB was associated with lower risk of MACE, even after accounting for achieved low-density lipoprotein cholesterol or non–high-density lipoprotein cholesterol, indicating that apoB provides incremental information. Achievement of apoB levels as low as ≤35 mg/dL may reduce lipoprotein-attributable residual risk after acute coronary syndrome. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01663402.gov; Unique identifier: NCT01663402.URL: https://www

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

10.1161/CIRCULATIONAHA.119.042551CIRCULATION140191578-158

Alirocumab and cardiovascular outcomes after acute coronary syndrome

BACKGROUN

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

BACKGROUN

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Background After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1.4-1.8 mmol/L with ezetimibe or statins reduces cardiovascular events in patients with an acute coronary syndrome and diabetes. However, the efficacy and safety of further reduction in LDL cholesterol with an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) after acute coronary syndrome is unknown. We aimed to explore this issue in a prespecified analysis of the ODYSSEY OUTCOMES trial of the PCSK9 inhibitor alirocumab, assessing its effects on cardiovascular outcomes by baseline glycaemic status, while also assessing its effects on glycaemic measures including risk of new-onset diabetes